INTERVIEW: New EU Drug Chief Says Biotech Copy Guidance Coming Capital.gr (press release) VX) blockbuster cancer drug rituximab loses patent protection. In contrast to traditional generics--copies of chemically synthesized drugs--biotech generics attempt to impersonate proteins that are made in living cells. "Having this guidance from us ... |
